Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Exp Hematol. 2021 Feb;94:1-10. doi: 10.1016/j.exphem.2020.11.005. Epub 2020 Nov 17.
RUNX1/RUNX1T1 is the most common fusion gene found in acute myeloid leukemia. Seminal contributions by many different research groups have revealed a complex regulatory network promoting leukemic self-renewal and propagation. Perturbation of RUNX1/RUNX1T1 levels and its DNA binding affects chromatin accessibility and transcription factor occupation at multiple gene loci associated with changes in gene expression levels. Exploration of this transcriptional program by targeted RNAi screens uncovered a crucial role of RUNX1/RUNX1T1 in cell cycle progression by regulating CCND2. This dependency results in a high vulnerability toward inhibitors of CDK4 and CDK6 and suggests new avenues for therapeutic intervention against acute myeloid leukemia.
RUNX1/RUNX1T1 是急性髓系白血病中最常见的融合基因。许多不同的研究小组的开创性贡献揭示了一个促进白血病自我更新和增殖的复杂调控网络。RUNX1/RUNX1T1 水平及其 DNA 结合的改变会影响与基因表达水平变化相关的多个基因座的染色质可及性和转录因子占据。通过靶向 RNAi 筛选对该转录程序的探索揭示了 RUNX1/RUNX1T1 通过调节 CCND2 在细胞周期进展中的关键作用。这种依赖性导致对 CDK4 和 CDK6 抑制剂的高敏感性,并为针对急性髓系白血病的治疗干预提供了新途径。